Implantable Infusion Pumps Market Projected to Grow to US$ 22.65 Billion by 2031, Driven by North America's Strong 41.5% Market Presence | DataM Intelligence

Leander, Texas - The Global Implantable Infusion Pumps Market was valued at approximately USD 16.24 billion in 2023 and is estimated to reach around USD 23.96 billion by 2031, growing at a CAGR of about 5.15% during the forecast period from 2024 to 2031.

This steady growth is driven by increasing prevalence of chronic conditions such as cancer, diabetes, and chronic pain which necessitate precise and continuous drug delivery. Advances in implantable pump technology, including more accurate dosing and improved patient safety features, along with rising surgical interventions and expanding healthcare infrastructure worldwide, are key factors accelerating market demand.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/implantable-infusion-pumps-market?ram

United States: Key Industry Developments

✅ October 2025: Several medtech companies have focused on advancements in programmable implantable infusion pumps offering precise drug delivery with programmable dosing capabilities targeting pain, cancer, and neurological conditions. These innovations are supported by FDA approvals for novel drug-device combinations enhancing clinical adoption.

✅ August 2025: Implantable infusion pumps with miniaturized device designs and biocompatible materials were introduced, improving patient outcomes and reducing complications. The oncology application segment particularly gained momentum with pumps delivering chemotherapy agents directly to tumor sites for targeted therapy.

✅ May 2025: Increased R&D investment by leading pharmaceutical and medical device companies led to new product introductions focusing on patient-controlled analgesia (PCA) pumps and insulin pumps integrated with smart technology features to facilitate customized, real-time dosage adjustments.

Japan: Key Industry Developments

✅ October 2025: The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan streamlined approval processes for new implantable infusion pump devices, facilitating quicker market access while maintaining high safety standards. This led to launches of pumps designed for chronic pain and cancer treatment with enhanced digital connectivity for remote monitoring.

✅ July 2025: Leading Japanese manufacturers introduced next-generation implantable infusion pumps incorporating closed-loop drug delivery systems, improving dosing accuracy through sensor technology and telemedicine integration, meeting Japan's regulatory focus on innovation and patient safety.

✅ March 2025: Insurance reimbursement policies were adjusted in Japan to cover expanded indications of implantable infusion pumps, driving increased adoption in specialty clinics for long-term drug delivery, especially for neurological disorders and diabetes management.

Key Merges and Acquisitions (2025):
✅ ICU Medical expanded its infusion pump portfolio in April 2025 by launching new devices and securing FDA clearance for advanced infusion pump technology, contributing to its market presence and innovative edge.

✅ Boston Scientific announced a strategic agreement in late 2024 to acquire Intera Oncology, which specializes in hepatic artery infusion pump technology, strengthening Boston Scientific's position in interventional oncology and implantable infusion pump applications.

✅ A significant collaboration in May 2025 saw Recotherapeutics plc partnering with Medtronic to develop next-generation implantable insulin pumps focused on improving treatment efficacy and reducing maintenance needs, signaling consolidation of expertise in pump technology.

✅ Leading players in the implantable infusion pump space have increasingly engaged in acquisitions, partnerships, and collaborations to boost technology integration and market reach, focusing on innovations such as AI-enabled drug delivery systems and multi-drug pumps.

Market Segmentation Analysis:
-By Product: Piston Type vs Creeping Type
Piston type infusion pumps and creeping type infusion pumps are key product segments. Programmable pumps (similar in technology to piston types) dominate with approximately 66.9% market share in 2024 due to their precision and adjustability for complex therapies. Creeping type pumps have smaller market shares relative to piston types.

-By Application: Cancer Treatment, Spasticity, Pain Management
Cancer treatment (oncology) is the leading application segment with around 27.5% market share in 2025, driven by the need for continuous drug delivery during chemotherapy. Pain management, including non-malignant and malignant pain, is also significant but secondary to cancer treatment. Spasticity treatment follows as a smaller but growing segment.

-By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centres
Hospitals hold the largest share by end-user segment due to their advanced care settings, critical care, and oncology unit demands. Specialty clinics and ambulatory surgical centres have smaller shares but are growing due to home care and outpatient treatment expansion.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=implantable-infusion-pumps-market?ram (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:
-Rising prevalence of chronic diseases such as cancer, diabetes, and chronic pain, which require long-term and precise drug delivery solutions.

-Increasing number of surgical procedures and implantations globally, particularly for oncology and pain management.

-Technological advancements such as miniaturization, improved battery life, programmable dosing, wireless connectivity, and AI integration for personalized and real-time drug delivery adjustments.

-Growing demand for patient-friendly, minimally invasive therapeutic options and outpatient care that reduce hospital stays.

-Expansion of healthcare infrastructure and rising healthcare spending, especially in emerging markets like Asia-Pacific.

-Regulatory support and increased R&D investments by key industry players accelerating innovation and new product development.

Regional Insights:
-North America: This region is the largest market for implantable infusion pumps, holding over 41.5% of the market share in 2024. The dominance is attributed to highly developed healthcare infrastructure, high healthcare expenditure, a significant aging population, and the high prevalence of chronic diseases like cancer and chronic pain that require long-term, precise drug delivery. The U.S. is the primary market in this region, driven by strong regulatory emphasis on patient safety and the adoption of advanced, smart infusion technologies.

-Europe: Europe holds a significant market share, driven by strong healthcare systems, an aging population, and a focus on cost-effectiveness and patient comfort. Germany is a prominent market within Europe, with well-established manufacturing industries and a strong emphasis on quality medical devices.

-Asia-Pacific: The Asia-Pacific region holds about 19.0% of the market share (as of 2024 for overall infusion pumps) and is projected to be the fastest-growing market, with a CAGR of around 10%. This rapid expansion is fueled by increasing government investments, improving healthcare infrastructure, a large patient pool, and growing awareness and adoption of advanced medical devices in countries like China and India.

-Latin America: The market in Latin America is expected to experience moderate growth, driven by an increasing incidence of chronic diseases and an aging population, particularly in countries like Brazil and Mexico.

-Middle East & Africa: This region is anticipated to show steady growth due to increased healthcare expenditures and the construction of new healthcare facilities. The market growth is linked to increasing local production of drugs and a high prevalence of chronic diseases.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/implantable-infusion-pumps-market?ram

Key Players:
Codman and Shurtleff | I-Flow Corp/Halyard Health | Flowonix Medical | Tricumed Medizintechnik | Intera Oncology | Tandem Diabetes Care Inc | Boston Scientific Corporation | Terumo Corporation | B. Braun | Medtronic PLC

Key Highlights (Top 5 Key Players) for Implantable Infusion Pumps Market:
-Medtronic PLC reported estimated market revenue exceeding USD 750 million in 2025, holding a dominant market share likely above 30% globally.

-B. Braun Melsungen AG generated approximately USD 460 million revenue in 2025, backed by its comprehensive infusion solution portfolio.

-Terumo Corporation recorded market revenue around USD 410 million in 2025, leveraging strong global healthcare networks.

-Flowonix Medical holds a significant position with revenues estimated near USD 180 million, driven by innovative product development.

-Codman and Shurtleff (a Johnson & Johnson company) accounted for close to USD 150 million in market revenue in 2025, maintaining strong market presence and technology expertise.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.